Amyloid Therapeutics Investment Landscape
Overview
flowchart TD
AMYLOID["AMYLOID"] -->|"associated with"| MICROGLIA["MICROGLIA"]
AMYLOID["AMYLOID"] -->|"associated with"| TAU["TAU"]
AMYLOID["AMYLOID"] -->|"associated with"| BACE1["BACE1"]
AMYLOID["AMYLOID"] -->|"associated with"| AUTOPHAGY["AUTOPHAGY"]
AMYLOID["AMYLOID"] -->|"associated with"| APOPTOSIS["APOPTOSIS"]
AMYLOID["AMYLOID"] -->|"associated with"| GFAP["GFAP"]
AMYLOID["AMYLOID"] -->|"associated with"| NEURON["NEURON"]
AMYLOID["AMYLOID"] -->|"associated with"| SOD1["SOD1"]
AMYLOID["AMYLOID"] -->|"associated with"| NLRP3["NLRP3"]
AMYLOID["AMYLOID"] -->|"associated with"| SNCA["SNCA"]
AMYLOID["AMYLOID"] -->|"associated with"| DEPRESSION["DEPRESSION"]
AMYLOID["AMYLOID"] -->|"inhibits"| ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
AMYLOID["AMYLOID"] -->|"activates"| GENES["GENES"]
AMYLOID["AMYLOID"] -->|"inhibits"| Alzheimer["Alzheimer"]
style amyloid fill:#4fc3f7,stroke:#333,color:#000
This page provides a comprehensive investment landscape analysis for amyloid-targeted therapeutics in Alzheimer's disease and related neurodegenerative conditions. [Amyloid-beta](/proteins/amyloid-beta) (Abeta) accumulation is a hallmark pathological feature of Alzheimer's disease, and therapeutic approaches targeting amyloid represent the largest segment of the AD therapeutic pipeline. [@clinical2026]
This analysis is based on clinical trial data from the NeuroWiki Clinical Trials Index, last updated 2026-03-12.
Pipeline Metrics
...Amyloid Therapeutics Investment Landscape
Overview
Mermaid diagram (expand to render)
This page provides a comprehensive investment landscape analysis for amyloid-targeted therapeutics in Alzheimer's disease and related neurodegenerative conditions. [Amyloid-beta](/proteins/amyloid-beta) (Abeta) accumulation is a hallmark pathological feature of Alzheimer's disease, and therapeutic approaches targeting amyloid represent the largest segment of the AD therapeutic pipeline. [@clinical2026]
This analysis is based on clinical trial data from the NeuroWiki Clinical Trials Index, last updated 2026-03-12.
Pipeline Metrics
| Metric | Value |
|---|---:|
| Total tracked amyloid-related trials | 667 |
| Active trials (recruiting/active/not-yet-recruiting) | 164 (24.6%) |
| Completed trials | 316 (47.4%) |
| Terminated/Withdrawn | 58 (8.7%) |
| Unknown status | 119 (17.8%) |
Trial Status Distribution
Active vs Historical Summary
| Category | Trial Count | Share |
|---|---|---:|
| Active | 164 | 24.6% |
| Recruiting | 99 | 14.8% |
| Not Yet Recruiting | 35 | 5.2% |
| Active Not Recruiting | 30 | 4.5% |
| Historical | 503 | 75.4% |
| Completed | 316 | 47.4% |
| Terminated | 36 | 5.4% |
| Withdrawn | 21 | 3.1% |
| Unknown | 119 | 17.8% |
Phase Distribution
| Phase | Trial Count | Share |
|---|---:|---:|
| Early Phase 1 | 9 | 1.3% |
| Phase 1 | 53 | 7.9% |
| Phase 1/Phase 2 | 11 | 1.6% |
| Phase 2 | 63 | 9.4% |
| Phase 2/Phase 3 | 5 | 0.7% |
| Phase 3 | 36 | 5.4% |
| Phase 4 | 7 | 1.0% |
| Not Applicable/NA | 483 | 72.4% |
Mechanism Breakdown
Amyloid-targeted therapeutics can be categorized by their mechanism of action:
1. Anti-Aβ Monoclonal Antibodies
The largest mechanism category includes antibodies designed to bind and clear amyloid-beta plaques or soluble oligomers.
Key Programs:
- Leqembi (Lecanemab) - Eisai/Biogen - Anti-Aβ protofibril antibody, FDA approved
- [Donanemab](/entities/donanemab) - Eli Lilly - Anti-Aβ plaque antibody, FDA approved
- Crenezumab - Roche/Genentech - Anti-Aβ oligomer antibody
- Gantenerumab - Roche - Anti-Aβ plaque antibody
- Solanezumab - Eli Lilly - Anti-Aβ soluble antibody
2. Aβ Aggregation Inhibitors
Small molecules designed to prevent the formation of or break down amyloid oligomers and plaques.
Key Programs:
- Contursi - Neurokine Therapeutics
- Curcumin derivatives - Multiple researchers
- NC-002 - New Century Therapeutics
3. BACE Inhibitors
[Beta-secretase](/entities/bace1) (BACE) inhibitors block the initial cleavage of [APP](/entities/app-protein) to produce Aβ.
Note: Several BACE inhibitors have failed in late-stage trials due to safety concerns (verubecestat, atabecestat, CNP520).
4. Gamma Secretase Modulators
Modulators of the gamma secretase enzyme that shift Aβ production toward shorter, less aggregation-prone isoforms.
Key Programs:
- GSM-17 - Astellas Pharma
- E2012 - Eisai
5. Aβ Vaccines
Active immunization approaches to induce anti-Aβ antibody production.
Key Programs:
- ACI-35 - AC Immune/Li-Iyonga - Liposome-based [tau](/proteins/tau) vaccine
- ABvac40 - Araclon Biotech - Aβ40 vaccine
- CAD106 - Novartis/Cytos Biotechnology - Aβ immunotherapeutic
6. Aβ Degradation Enhancers
Approaches to enhance the clearance of Aβ through enzymatic degradation or cellular clearance mechanisms.
7. PET Imaging Agents
Diagnostic agents for amyloid plaque imaging:
- Pittsburgh Compound B (PiB) - Research use
- Florbetapir (Amyvid) - FDA approved for PET imaging
- Florbetaben (Neuraceq) - FDA approved for PET imaging
- Flutemetamol (Vizamyl) - FDA approved for PET imaging
Academic Medical Centers
| Sponsor | Trial Count |
|---|---:|
| Institute for Neurodegenerative Disorders | 11 |
| National Taiwan University Hospital | 10 |
| Chang Gung Memorial Hospital | 9 |
| Washington University School of Medicine | 9 |
| University of Pittsburgh | 8 |
| Massachusetts General Hospital | 8 |
Pharmaceutical Companies
| Sponsor | Trial Count |
|---|---:|
| Eli Lilly and Company | 9 |
| Affiris AG | 8 |
| Pfizer | 6 |
| Cyclo Therapeutics, Inc. | 6 |
| Eisai | 5 |
| Biogen | 4 |
| Roche | 4 |
| Novartis | 3 |
| AstraZeneca | 2 |
Pipeline Gaps and Opportunities
Unmet Needs
Disease-modifying therapies for early intervention - Most advanced programs target moderate-to-severe AD; need for prodromal/preclinical trials
Combination approaches - Limited combination therapy signals in current pipeline
Biomarker-positive enrichment - Only 9.2% of AD trials include biomarker endpoints
Non-antibody modalities - Heavy reliance on monoclonal antibodies; need for small molecule and gene therapy approachesOpportunity Areas
Anti-oligomer-specific antibodies - Targeting toxic soluble oligomers rather than plaques
Peripheral sink approaches - Reducing peripheral amyloid to drive brain clearance
Multi-target approaches - Combined Aβ/tau targeting
Genetic risk stratification - APOE4-enriched trialsInvestment Themes
Consolidation Phase
The amyloid therapeutic space has consolidated following the FDA approvals of Leqembi and Donanemab. Investment is shifting toward:
Real-world evidence generation - Post-approval studies
Early intervention - Preclinical and prodromal AD
Biomarker development - Plasma and PET biomarkers for patient selectionKey Challenges
Safety monitoring - ARIA (amyloid-related imaging abnormalities) requires careful monitoring
Treatment duration - Long-term treatment effects unclear
Access and reimbursement - Pricing and coverage decisions pendingCross-Links to Related Pages
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-pathway)
- [Amyloid-beta Protein](/proteins/amyloid-beta-protein)
- [Alzheimer's Disease Investment Landscape](/diseases/alzheimers-disease-investment-landscape)
- [Anti-Tau Therapeutics Investment Landscape](/therapeutics/anti-tau-therapeutics)
Clinical Trials
For current clinical trials targeting amyloid-beta and related pathways in Alzheimer's disease, see:
- [Clinical Trials: Alzheimer's Disease](/clinical-trials/alzheimers-disease)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Amyloid Cascade Pathway](/mechanisms/amyloid-cascade-hypothesis)
- [Anti-Tau Therapeutics](/proteins/tau)
- [Tau Protein](/proteins/tau)
- [Beta-Secretase Inhibitors](/genes/ret)
External Links
- [ClinicalTrials.gov - Alzheimer's Disease](https://clinicaltrials.gov/search?cond=Alzheimer+Disease)
- [FDA - Alzheimer's Disease Drug Approvals](https://www.fda.gov/drugs/conditions-we-work-drug-investigational-new-drugs/fda-approves-new-alzheimers-drug)
- [Alzheimer's Association](https://www.alz.org/)
References
Clinical trial data from [NeuroWiki Clinical Trials Index](/clinical-trials), updated 2026-03-12. See also:, ClinicalTrials.gov Alzheimer's Trials (2026)Pathway Diagram
The following diagram shows the key molecular relationships involving Amyloid Therapeutics: Investment Landscape Analysis discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)